Abiomed CEO Minogue on DoJ probe, FDA call

February 6, 2013 by MassDevice staff

A U.S. Justice Dept. investigation and the FDA's decision to require pre-market approval for Abiomed's Impella heart pump leave CEO Michael Minogue unfazed.


Cardiologists aren't paying much attention to the noise around Abiomed (NSDQ:ABMD) and its flagship medical device, the Impella heart pump, at least according to chairman, president & CEO Michael Minogue.

That noise centered around a pair of events during the 4th quarter: news of a U.S. Justice Dept. probe into its marketing of the Impella pump and an FDA decision to require the device to undergo a more rigorous approval process.

The Danvers, Mass.-based medical device company revealed the DoJ probe last year, sending share prices down more than 30% in a day. A month later a federal watchdog agency panel voted to require that the Impella undergo the FDA's pre-market approval protocol, which ordinarily requires extensive clinical trials before approval is granted.

Sign up to get our free newsletters delivered right to your inbox.

Minogue downplayed the effect on Abiomed's cardiologist customers after he was asked during a conference call with investors about all the "noise" surrounding the 1-2 punch.